Grants & Funding

CARRA-Arthritis Foundation Health Equity Research Grant


Not currently accepting applications.

CARRA was founded on principles of inclusivity and collaboration and we continue to promote our mission and vision with these thoughts as our core values. The disproportionate effect of COVID-19 on people of color has emphasized the health consequences of our social system and brought overdue attention to the health disparities we see affecting our patient communities every day. As a healthcare research organization, we have a role in creating a better future for all of our communities, both through the research we conduct and in the way we engage with people within our organization, among our partners and throughout the communities around us.

This CARRA-Arthritis Foundation grant mechanism was established to support research which addresses topics along the health equity research spectrum, which includes, but is not limited to:

  • Methods to improve identification and measurement of root causes of health inequities in pediatric rheumatology;
  • Strategies to increase representation of minoritized groups in pediatric rheumatology research;
  • Translational research that identifies how social determinants of health are embodied to affect disease onset, severity, and outcomes; and/or
  • Interventions to reduce or eliminate health disparities and/or address health inequities in pediatric rheumatology.

Racial and ethnic minoritized populations and other groups that experience health disparities bear disproportionate burdens of disease and illness, due in part to greater exposure to systemic adverse social, structural, and institutional factors (e.g., poverty, low quality education, chronic psychosocial stress) and/or reduced access to health-promoting aspects of the environment (e.g., opportunities for enhancing physical activity, quality health care, neighborhood resources). The disproportionate effect of COVID-19 on people of color has exemplified the health consequences of our social system and brought overdue attention to the health disparities we see affecting our patient communities every day. CARRA was founded on principles of inclusivity and collaboration. As a healthcare research organization, CARRA has a role in creating a better future for all of our communities through the research we conduct and in the way we engage with people within our organization, among our partners and throughout the communities around us. A focus on health equity requires efforts to better understand and modify factors that put pediatric rheumatology populations experiencing health disparities at a disadvantage, and to enhance factors that increase the likelihood for achieving positive health outcomes.


CARRA-Arthritis Foundation Health Equity Research Grant Required Submission Materials

  • Letter of Intent (LOI) due September 1 (see details below)
  • Project Summary/Abstract (300 word max)
  • Lay Summary (150 word max)
  • Specific Aims (1 page limit) (Download template: WORD)
  • Research Plan (5 page limit) (Download template: WORD)
  • Project Timeline (3 page limit) (Download template: WORD)
  • References (no page limit) (Download template: WORD)
  • Year 1/Year 2 Budget Tables (2 page limit) (Download template: WORD)
    • All Primary Investigators (PI) are required to dedicate effort on their projects which must be noted on the budget table. Requesting salary support is optional. A letter of support from your division chief documenting that the % effort is available, and confirming investigator salary (if applicable) must be submitted with each application. If the PI is the division chief, a letter from the Department Chairperson is required.
  • Budget Justification (Download template: WORD)
    • Total costs of salary support for PI(s) and Co-I(s) must not exceed 50% of total project costs.
    • CARRA will allow up to 8% F&A (indirect) costs which must be incorporated into the project budget below. If indirect costs are requested, total costs for this project must not exceed $100,000.
    • Poster printing and publication costs are not allowed.
    • Travel expense requests are not permitted unless required for the conduct of research. Travel expenses to attend meetings to present this work, for example, are not allowed.
    • Other expenses should be discussed with CARRA personnel prior to application submission.
  • NIH-formatted Biosketches for all Principal Investigator(s), Co-Principal Investigator(s), and all Co-Investigator(s) (limit 5 pages per biosketch; please combine all biosketches into one PDF with the PI(s) biosketch listed first.)
  • Letters of Support
    • Required for budgets that include investigator effort (include letter from division chief documenting that % effort is available, and confirming investigator salary). Total costs salary support must not exceed 50% of total project costs.
    • Letters of support from collaborators, mentors and institution are highly recommended.
    • Letters of Support from RROC for registry-related applications requesting collection of new data or sample collection. New data is defined as anything that is not currently collected through the Registry's CRFs. New samples include any new patient cohort or sample types that are not currently collected through CARRA's standard Type 1 or Type 2 kits.
    • Please see bottom of page for full guidelines regarding use of CARRA Registry data and collection of biosamples.
  • Research Assurances
    • Submit documentation of an Institutional Review Board (IRB) review. Funds will not be released until either 1) IRB approval letter or 2) IRB waiver/documentation that IRB has determined your project is exempt from IRB review is received.
    • Awards will be relinquished if IRB approval or an IRB waiver is not received by 6 months after the project period start date. 
  • Appendix (limit 1 attachment)

Applicants must use the templates provided when submitting their final applications. CARRA Staff is available to assist with the application process and to answer questions. Contact us by emailing [email protected].

APPLICATIONS NOT FOLLOWING THESE INSTRUCTIONS WILL NOT BE CONSIDERED.


Important Information for Health Equity Research Grant Submissions

Read the CARRA-Arthritis Foundation Health Equity Research Grant instructions carefully. Be sure to be compliant with formatting instructions and page limits. Use of the document templates provided above is REQUIRED. Submit your completed CARRA-Arthritis Foundation Health Equity Research Grant application via the online grant submission system.

Application deadline for the CARRA-Arthritis Foundation Health Equity Research Grant:

Letter of Intent: September 1
Fall Cycle: October 1

  • A maximum of 2 grants will be awarded per year.
  • The funding limit of this grant mechanism is $150,000.
  • Salary/Effort: Letters of support are required for budgets that include investigator effort (include letter from division chief documenting that % effort is available, and confirming investigator salary). Total costs salary support for the Principal Investigator(s) and Co-Investigator(s) must not exceed 50% of total project costs.
  • This is a total costs award. If indirects are requested, they must be inclusive of the maximum funding amount of $150,000. Indirects may not exceed 8%.
  • Awardees from previous grant cycles who wish to submit grant applications for the upcoming deadline must have all active Small, Large, or Fellow CARRA-Arthritis Foundation grant projects completed.
  • The project period is two years. The budget justification provided must indicate how funds are to be allocated for each year and will be paid out on an annual basis.
  • Funds will be provided to the awardee’s institution in two payments to be set up in a sundry account and used by the principal investigator according to the project budget.
    • Year 1 funding as outlined in the budget justification will be provided upfront.
    • Year 2 funding as outlined in the budget justification will distributed following submission and approval of an interim progress report at the end of year 1. Release of Year 2 funds may be contingent on IRB annual re-approval.
  • Applications proposing the collection of any new data or biosamples via the CARRA Registry must include a letter of support (LOS) from CARRA's Research and Registry Oversight Committee (RROC). (see details below)
  • For projects requesting budget support to cover Registry costs, requested funds will be held at CARRA and paid directly to DCRI.
  • The project period is two years beginning February 15.
  • First-time CARRA-Arthritis Foundation grant awardees are required to participate in a brief orientation.
  • A final project report is required no later than 45 days after the project period end date.
  • If the PI is unable to complete the project, any unexpended balance will be returned to CARRA.
  • Awardees are expected to submit an abstract and attend the CARRA Annual Meeting(s) until the project is complete/final.
 

Letter of Intent (LOI)

LOIs are required when submitting Health Equity Research Grant applications and are due 30 days prior to the application deadline. The LOI should be a one-page signed letter which includes:

  • A summary of the full proposal with a short description of aims of the project involved, with a clear indication of how the aims align with the intent of this application request
  • Name of the PI(s) and submitting institution
  • A list of key personnel and role(s)
  • A description of how the project aligns with CARRA's mission.

The LOI MUST be on institutional letterhead and signed by the Principal Investigator(s).

Submit Letters of Intent to [email protected].

While the LOI is an administrative requirement, it is for informational purposes only. Approval from CARRA is not needed to proceed with the full application. Investigators will receive confirmation that their LOI has been received by the CARRA grants office.

 

Submission and Review Process

Applications will be submitted via an online submission form. The CARRA Grants Manager will conduct an administrative review to ensure all necessary application materials have been submitted. Reviews will be conducted by the Scientific Review Committee (SRC) and additional patient/caregiver reviewers. SRC recommendations and scores will then be reviewed by the Internally Funded Research Oversight Committee (IROC) for final funding decisions. Applicants will be notified via email and must return a signed award acknowledgement and other appropriate documentation as needed before funds are distributed.

 

Review Criteria

In addition to considering strengths of the scientific approach, capacity of the investigative team and their environment to complete the work, innovative aspects of the project, and relevance of the work to the mission of CARRA and its stakeholders, much weight will be given in the review process to the significance of the proposal in terms of the following:

  • Impact of the proposed study on addressing health equity
  • Consideration of diversity, equity, and inclusion (DEI) practices and representation within the research team
  • Engagement of relevant stakeholders, including patients/caregivers
 

Eligibility

  • The project PI for all grants must be a current CARRA member who is up to date on membership dues and membership information (location, contact information, and membership status) is up-to-date.
  • Awardees from previous grant cycles who wish to submit grant applications for the upcoming deadline must have all active CARRA-Arthritis Foundation grant projects completed and have submitted a final progress report (template available on the CARRA website).
  • MD applicants must be at a faculty level to be eligible to submit proposals.
  • Voting Members, Emeritus Members, Research Professional Member - Investigators, Research Professional Member - Research Coordinator Members, Associate Physician Members, and Trainee Members are eligible to submit proposals.
  • All grants must be submitted by or have a pediatric rheumatologist named as a Co-Investigator.
  • Research Coordinator Member- Other, Health Care Professional Members, Fellow Members, and CARRA Executive Committee and Board of Directors members are not eligible.
 

Funding and Funding Period

  • Awards are total costs. Up to 8% F&A (indirect) costs are allowed, but costs must be incorporated into the project budget and not exceed the advertised award amount.
  • Funds will be provided to the awardee’s institution in two payments to be set up in a sundry account and used by the principal investigator according to the project budget.
    • Year 1 funding as outlined in the budget justification will be provided upfront.
    • Year 2 funding as outlined in the budget justification will distributed following submission and approval of an interim progress report at the end of year 1. Release of Year 2 funds may be contingent on IRB annual re-approval.
  • Publication, presentation, and travel costs should not be requested/included, unless the travel is an essential part of performing the research. Other expenses should be discussed with CARRA personnel prior to application submission.
  • Salary support will be limited to a base-salary cap of $200,000 but can include payment of local fringe rates (on top of $200,000 salary cap).
  • Please review CARRA’s statement of direct and indirect support.
  • All awards are for two years, with funding beginning February 15 of the following year.
  • Applicants will be notified of funding decisions in January.
  • If the project is not completed within the project period, the award recipient may request a no-cost extension (NCE) for up to 12 months. Requests for NCEs can be made up to 90 days prior, but no less than 30 days prior, to the project end date. An interim progress report must be submitted with the NCE Request Form, both of which are available on the CARRA website.
 

Reporting & Publications

  • Awardees must submit a year 1 progress report 30 days prior to the end of the first year of the project period in order to request the release of year 2 funds.
  • Awardees must submit a final progress report no later than 45 days after the project period end date.
  • Timely provision of progress reports is required for future eligibility for CARRA-Arthritis Foundation grants.
  • Awardees are expected to submit abstracts to CARRA and present their findings at the CARRA Annual Scientific Meeting(s) until the project is complete/final.
  • Awardees are expected to submit a peer-reviewed abstract to a scientific meeting based on the funded project.
  • All awardees of CARRA-Arthritis Foundation funding must abide by the procedures outlined in the CARRA Publications Policy when presenting/publishing findings from their projects. This includes submitting all abstracts and manuscripts to the CARRA Publications Committee for approval prior to submission and acknowledging the support of CARRA and the Arthritis Foundation by including the following language: “The authors wish to acknowledge CARRA, and the ongoing Arthritis Foundation financial support of CARRA.” Refer to the current Publications and Presentation Guidelines for complete details.

IMPORTANT UPDATE FOR GRANT APPLICANTS USING CARRA REGISTRY DATA/SAMPLES

Grant applicants that intend to utilize the CARRA Registry or CARRA-related data and/or samples (including Legacy Registry and APPLE data/samples) must receive approval from the CARRA Data Sample Share Committee (DSSC) prior to submitting their grant applications. These requests take 4-6 weeks to process.

For more information on requesting data/samples and to access the request form, please visit the CARRA Data and Samples Request area of the wiki.

The deadline for 2021 Fall Grant Cycle DSSC requests is August 20.

 

Grant applications that propose collection of any new data or biosamples via the CARRA Registry must include a letter of support (LOS) from CARRA’s Research and Registry Oversight Committee (RROC).

The deadline for 2021 Fall Grant Cycle RROC requests is August 20.

 

Applications that do not meet these request deadlines will result in an administrative decline. If you have any questions regarding this requirement, email [email protected].